Clinical trial
Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma - Carboplatin, Docetaxel and Capecitabine (CTX) or Epirubicin, Oxaliplatin and Capecitabine: a Randomised Phase 2 Trial.
NCT02177552 is registered in ClinicalTrials.gov with Rigshospitalet, Denmark as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma - Carboplatin, Docetaxel and Capecitabine (CTX) or Epirubicin, Oxaliplatin and Capecitabine: a Randomised Phase 2 Trial.
- Lead sponsor
- Rigshospitalet, Denmark
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 30, 2014
- Completion date
- November 30, 2019
- Enrollment
- 98 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.